Analysis by Type {IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M)}; by End User (Drug Stores & Retail, Hospital, and Online Pharmacies); and by Product (Xifaxan, Linzess, Amitiza, Viberzi, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035
Buy Now
The global irritable bowel syndrome drugs market is estimated to garner a revenue of USD 5 Billion by the end of 2035 by growing at a CAGR of ~14% over the forecast period, i.e., 2023 – 2035. Further, the market generated a revenue of USD 2 Billion in the year 2022. The growth of the market can be attributed to the increasing number of elderly people who are prone to different types of gastrointestinal diseases. Further, the growing prevalence of gastrointestinal diseases amongst other population group, an increase in the consumption of unhealthy foods, and rising stress levels among people across the globe are also expected to add to the market growth. The estimated prevalence of irritable bowel syndrome in the United States is between 11% and 14% and this share is predicted to increase further in the years to come.
Get more information on this report:Download Sample PDF
In addition to these, factors that are believed to fuel the market growth of irritable bowel syndrome drugs include the rise in over-the-counter drug availability, soaring investments, and collaboration between major key players to discover effective treatments for IBS. For instance, on June 9, 2022, the biopharmaceutical company Ferring B.V. announced a strategic partnership with the innovation-focused global biopharma company I-MAB Biopharma Co., Ltd. to advance the development of olamkicept, a selective interleukin-6 (IL-6) trans-signaling inhibitor for inflammatory bowel disease (IBD) and associated inflammatory conditions. Additionally, the growing number of awareness campaigns on the management of irritable bowel syndrome is predicted to present the potential for market expansion over the projected period.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~14% |
|
Base Year Market Size (2022) |
~ USD 2 Billion |
|
Forecast Year Market Size (2035) |
~ USD 5 Billion |
|
Regional Scope |
|
Growth Drivers
Growing Prevalence of Diarrhea in Children – On account of the increasing prevalence of gastrointestinal disorders in children, including diarrhea, constipation, and bowel incontinence, the market is expected to expand more in the upcoming years. Diarrhea is listed as the second most typical cause of death in children under the age of five by the World Health Organization. Each year, diarrhea kills about 500 000 children under the age of five. Around 2 billion children worldwide have diarrheal sickness every year.
Rising Geriatric Population – Elderly population is more prone to bowel incontinence and the rising number of elderly populations across the globe is estimated to drive market growth. The percentage of individuals over 60 in the world will nearly double from 12 to 22% between 2015 and 2050. In 2020, there were more people over the age of 60 than children under five and by 2050, it is predicted that 80% of the world's old people will live in low- and middle-income countries.
Increasing Health Spending – According to the most recent expenditure data, global health spending has grown over the past 20 years, doubling in real terms to reach USD 8.5 trillion in 2019 and 9.8% of GDP, up from 8.5 percent in 2000. It is predicted that this boom would continue over the forecast period.
Growing Incidences of Spinal Cord Injuries – It is expected that patients with chronic illnesses and disabilities, including spinal cord injuries, experience bowel incontinence more severely, which is anticipated to drive the market growth. It was discovered that between 300,000 and 500,000 people worldwide experience spinal cord injuries every year.
Rising Cases of Hemorrhoids – Hemorrhoids can also be referred to as piles. Inflamed veins in the lower rectum and anus are hemorrhoids. Bowel incontinence can result from this swelling, thereby raising the need for hemorrhoids drugs, which is anticipated to drive the market growth. At least 50% of Americans over the age of 50 who have hemorrhoids experience obvious symptoms.
Challenges
Side effects of IBS drugs - The increasing concern amongst individuals for the side effects associated with the consumption of IBS drugs is one of the major factors predicted to slow down the market growth. For instance, pancreatitis, a serious and more common pancreatic inflammation, can arise from the dual mu-opioid nicotinic receptor eluxadoline, which is employed to address digestive problems with incontinence in some people.
Low awareness among people in low and middle-income countries for these drugs
Lack of medical reimbursement policies for treatment of IBS
The global irritable bowel syndrome drugs market is segmented and analyzed for demand and supply by type into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS (IBS-M). Out of these, the IBS with diarrhea (IBS-D) segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing prevalence of diarrhea among all age groups and the rising adoption of unhealthy lifestyles including the consumption of fast food and alcohol. For instance, diarrheal illnesses are believed to be responsible for 300 annual pediatric fatalities and 167,000 hospitalizations in the US.
The North American irritable bowel syndrome drugs market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed to the increasing frequency of fecal incontinence and the availability of efficient treatment options in the region. For instance, 50 to 70 patients out of every 100 nursing home residents and 18 to 33 patients out of every 100 hospitalized patients, respectively, suffer from fecal incontinence. Fecal incontinence affects 7 to 15 persons out of every 100 who are not patients or residents of nursing homes or hospitals. In addition, the region's supportive health policies and expanding healthcare industry are anticipated to boost the market expansion during the course of the anticipated period.
Our in-depth analysis of the global irritable bowel syndrome drugs market includes the following segments:
|
By Type |
|
|
By Product |
|
|
By End User |
|
Abbott Services
IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
Indegene a provider of technology-driven healthcare solutions, and metaMe Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: Increasing incidences of irritable bowel syndrome and growing availability of over the counter drugs are estimated to boost market growth.
Ans: The market is anticipated to attain a CAGR of ~14% over the forecast period, i.e., 2023 – 2035.
Ans: Lack of awareness regarding IBS treatment and the side effects of IBS drugs are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca, GlaxoSmithKline Plc, and Johnson & Johnson Services, Inc.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by type, product, end user, and by region.
Ans: The IBS with diarrhea (IBS-D) segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
